Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that GZC8072 tablets independently developed by Ganli Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, are undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject. GZC8072 tablets are a new generation biased ultra-long-acting polypeptide oral preparation. Clinical trials are being carried out for indications for obesity, overweight, and type 2 diabetes.

Zhitongcaijing · 1d ago
Zhitong Finance App News, Ganli Pharmaceutical (603087.SH) announced that GZC8072 tablets independently developed by Ganli Pharmaceutical Shandong Co., Ltd., a wholly-owned subsidiary of the company, are undergoing phase I clinical trials in China, and recently successfully completed the administration of the first test subject. GZC8072 tablets are a new generation biased ultra-long-acting polypeptide oral preparation. Clinical trials are being carried out for indications for obesity, overweight, and type 2 diabetes.